Microbiome Connect: USA 2022

    The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic emerges, drug developers will have the opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications. Furthermore, the manufacturing challenges associated with reaching commercialization specific to microbiome-based drugs will be addressed in depth. With talks from Live Biotherapeutic Product manufacturing experts, including the Head of CBER, on topics including how to handle USP 61/62, and achieving co-culturing capabilities. Join us to hear from microbiome biotechs, pharma voices, investment bodies, and more on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.

    Event Venue: The Westin Boston Seaport District 425 Summer Street, Boston, MA, 02210
    Event Date: November 16-17 2022
    Event website: www.microbiomeconnectusa.com
    Event Organizer: Kisaco Research
    Contact number: +44 (0)20 3696 2920
    Email ID: events@kisacoresearch.com


    Organiser: Kisaco Research

    Kisaco Research works with the early adopters and leaders of growth markets in driving their respective industries forward and in providing the right knowledge, learning and social opportunities to stimulate business growth quickly and effectively.

    Kisaco Research produces, designs and hosts B2B industry conferences and exhibitions. Our platforms are neutral, so that our attendees get the right information from the most relevant people.